Leisha A. Emens MD PhD

Sitert av

	Alle	Siden 2020
Sitater	22872	15172
h-indeks	68	48
i10-indeks	154	120

3500

1750

875

2625

2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202578 105 147 257 259 244 210 321 281 319 433 381 411 585 690 912 1658 2536 3379 3424 2848 2541 391

Offentlig tilgang

Vis alle

58 artikler

6 artikler

tilgjengelige

ikke tilgjengelige

Basert på finansieringsmandater

Medforfattere

Elizabeth JaffeeJohns Hopkins University School of MedicineVerifisert e-postadresse på jhmi.edu
Richard Todd ReillyPercipient Consulting, LLCVerifisert e-postadresse på percipient-consulting.com
Ashley Cimino-MathewsThe Johns Hopkins University School of MedicineVerifisert e-postadresse på jhmi.edu
Pedram ArganiProfessor of Pathology and Oncology, Johns Hopkins UniversityVerifisert e-postadresse på jhmi.edu
Antonio C. Wolff, MD, FACP, FASCOProfessor of Oncology, Johns Hopkins UniversityVerifisert e-postadresse på jhmi.edu
Rita NandaAssociate Professor, The University of ChicagoVerifisert e-postadresse på medicine.bsd.uchicago.edu
jean-pascal machielsProfesseur, Université catholique de LouvainVerifisert e-postadresse på uclouvain.be
Elizabeth D ThompsonAssistant Professor of Pathology, The Johns Hopkins University School of MedicineVerifisert e-postadresse på jhmi.edu
Paolo A. AsciertoIstituto Nazionale Tumori Fondazione "G. Pascale", Napoli, ItalyVerifisert e-postadresse på istitutotumori.na.it
Ben Ho ParkVanderbilt University Medical Center, Johns Hopkins University, University of PennsylvaniaVerifisert e-postadresse på jhmi.edu
Elizabeth Garrett-MayerAmerican Society of Clinical OncologyVerifisert e-postadresse på asco.org
Rachel LeiRadiation Oncology, Rocky Mountain Cancer Centers, US OncologyVerifisert e-postadresse på usoncology.com
Matthew HellmannMemorial Sloan Kettering Cancer CenterVerifisert e-postadresse på mskcc.org
Peng HuangJohns Hopkins UniversityVerifisert e-postadresse på jhmi.edu
Peter S. KimNational Cancer InstituteVerifisert e-postadresse på mail.nih.gov
Evan J. LipsonAssociate Professor of Oncology, Johns Hopkins UniversityVerifisert e-postadresse på jhmi.edu
William L. RedmondMember (Full Professor), Earle A. Chiles Research Institute, Providence Cancer InstituteVerifisert e-postadresse på providence.org
Leslie CopeJohns Hopkins UniversityVerifisert e-postadresse på jhmi.edu
Yao LuYale UniversityVerifisert e-postadresse på yale.edu
Toby C. Cornish, MD, PhDProfessor of Pathology, Medical College of WisconsinVerifisert e-postadresse på mcw.edu

Følg

Leisha A. Emens MD PhD

Professor of Medicine

Verifisert e-postadresse på upmc.edu

cancer immunotherapy breast cancer


Tittel Sorter etter sitater Sorter etter år Sorter etter tittel	Sitert av Sitert av	År
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer P Schmid, S Adams, HS Rugo, A Schneeweiss, CH Barrios, H Iwata, ... New England journal of medicine 379 (22), 2108-2121, 2018	4176	2018
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results … P Schmid, HS Rugo, S Adams, A Schneeweiss, CH Barrios, H Iwata, ... The lancet oncology 21 (1), 44-59, 2020	1219	2020
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study LY Dirix, I Takacs, G Jerusalem, P Nikolinakos, HT Arkenau, ... Breast cancer research and treatment 167, 671-686, 2018	825	2018
The interplay of immunotherapy and chemotherapy: harnessing potential synergies LA Emens, G Middleton Cancer immunology research 3 (5), 436-443, 2015	803	2015
Breast cancer immunotherapy: facts and hopes LA Emens Clinical cancer research 24 (3), 511-520, 2018	797	2018
Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study LA Emens, C Cruz, JP Eder, F Braiteh, C Chung, SM Tolaney, I Kuter, ... JAMA oncology 5 (1), 74-82, 2019	761	2019
Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape LA Emens, PA Ascierto, PK Darcy, S Demaria, AMM Eggermont, ... European journal of cancer 81, 116-129, 2017	607	2017
Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2 … JPH Machiels, RT Reilly, LA Emens, AM Ercolini, RY Lei, D Weintraub, ... Cancer research 61 (9), 3689-3697, 2001	553	2001
Targeting adenosine for cancer immunotherapy RD Leone, LA Emens Journal for immunotherapy of cancer 6, 1-9, 2018	518	2018
Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response AM Ercolini, BH Ladle, EA Manning, LW Pfannenstiel, TD Armstrong, ... Journal of Experimental Medicine 201 (10), 1591-1602, 2005	481	2005
Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade LA Emens Expert review of anticancer therapy 12 (12), 1597-1611, 2012	467	2012
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis LA Emens, S Adams, CH Barrios, V Diéras, H Iwata, S Loi, HS Rugo, ... Annals of Oncology 32 (8), 983-993, 2021	379	2021
Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood MJ Higgins, D Jelovac, E Barnathan, B Blair, S Slater, P Powers, J Zorzi, ... Clinical cancer research 18 (12), 3462-3469, 2012	378	2012
PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas A Cimino-Mathews, E Thompson, JM Taube, X Ye, Y Lu, A Meeker, H Xu, ... Human pathology 47 (1), 52-63, 2016	375	2016
Antagonists of PD-1 and PD-L1 in cancer treatment EJ Lipson, PM Forde, HJ Hammers, LA Emens, JM Taube, SL Topalian Seminars in oncology 42 (4), 587-600, 2015	343	2015
Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC) LA Emens, FS Braiteh, P Cassier, JP Delord, JP Eder, M Fasso, Y Xiao, ... Cancer Research 75 (15_Supplement), 2859-2859, 2015	336*	2015
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre … LA Emens, FJ Esteva, M Beresford, C Saura, M De Laurentiis, SB Kim, ... The lancet oncology 21 (10), 1283-1295, 2020	316	2020
Chemoimmunotherapy: reengineering tumor immunity G Chen, LA Emens Cancer Immunology, Immunotherapy 62, 203-216, 2013	287	2013
Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer L Fong, A Hotson, JD Powderly, M Sznol, RS Heist, TK Choueiri, ... Cancer discovery 10 (1), 40-53, 2020	280	2020
Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment PA Philip, M Mooney, D Jaffe, G Eckhardt, M Moore, N Meropol, L Emens, ... Journal of Clinical Oncology 27 (33), 5660-5669, 2009	276	2009

Systemet kan ikke utføre handlingen. Prøv på nytt senere.

Artikler 1–20

Sitater per år

Duplikatsitater

Sammenslåtte sitater

Legg til medforfattereMedforfattere

Følg

Sitert av

Medforfattere